Montreux Equity Partners is private investment firm dedicated to building great healthcare companies. Our mission is to generate industry leading returns by investing in superior businesses that meet the most compelling healthcare needs of tomorrow. Montreux is currently investing out of its fourth fund, MEP IV, a $250 million vehicle. The firm is located in Menlo Park, California.

Montreux’s investment team brings more than 75 years of industry experience to its investment activity. Our team has served as founders, leaders, investors, and board members in more than 45 life science companies over the past 25 years. Our principals bring both domestic and international capabilities to our investment focus.

Our portfolio companies benefit from the experience that comes from our involvement in building numerous successful companies. A historical sample of these companies includes:

• MAKO Surgical (NASDAQ: MAKO)
• Aryx Therapeutics (NASDAQ: ARYX)
• Transcept Pharmaceuticals (NASDAQ: TSPT)
• NovaCardia (acquired by Merck, 2007)
• Orexigen Therapeutics (NASDAQ: OREX)
• NeurogesX (NASDAQ: NGSX)
• Cerexa (acquired by Forest Laboratories, 2007)
• Somaxon Pharmaceuticals (NASDAQ: SOMX)
• Peninsula Pharmaceuticals (acquired by Johnson & Johnson in 2005)
• Questcor Pharmaceuticals (NASDAQ: QCOR)
• Coalescent Surgical (acquired by Medtronic in 2004)
• Integrated Biosystems (acquired by STEDIM in 2004)
• Conceptus (NASDAQ: CPTS)
• Enteric Medical (acquired by Boston Scientific in 2002)
• Interventional Technologies (acquired by Boston Scientific in 2001)
• ProDuct Health (acquired by Cytyc in 2001)
• Collagen (acquired by Inamed in 1999)
• Innovasive Devices (acquired by Johnson & Johnson in 1998)
• Prograft Medical (acquired by W.L. Gore in 1997)
• Target Therapeutics (acquired by Boston Scientific in 1997)
• Oclassen Pharmaceuticals (acquired by Watson Pharmaceuticals in 1997)